middle.news
Radiopharm’s RAD 101 Hits 92% Concordance in Brain Metastases Trial
9:44am on Monday 15th of December, 2025 AEDT
•
Healthcare
Read Story
Radiopharm’s RAD 101 Hits 92% Concordance in Brain Metastases Trial
9:44am on Monday 15th of December, 2025 AEDT
Key Points
92% concordance with MRI in interim Phase 2b trial
RAD 101 targets fatty acid synthase for brain metastases imaging
FDA Fast Track designation supports accelerated development
Trial enrollment at 50%, pivotal study planned by end 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE